VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

Psuedorabies DNA vaccine encoding IE180 protein
Vaccine Information
  • Vaccine Name: Psuedorabies DNA vaccine encoding IE180 protein
  • Target Pathogen: Pseudorabies virus
  • Target Disease: Aujeszky's disease
  • Vaccine Ontology ID: VO_0004039
  • Type: DNA vaccine
  • Status: Research
  • IE180 gene engineering:
    • Type: DNA vaccine construction
    • Description:
    • Detailed Gene Information: Click Here.
  • DNA vaccine plasmid:
    • DNA vaccine plasmid name:
    • DNA vaccine plasmid VO ID: VO_0000158
  • Immunization Route: Gene Gun
Host Response

Mouse Response

  • Host Strain: BALB/c, C3H/HeJ, and C57BL/6
  • Vaccination Protocol: Two shots of DNA/mouse (1 /Ag/shot) were delivered with helium at 200 psi via the Helios Gene Gun to the shaven abdominal skin of 10 male mice of each strain, BALB/c, C57BL/6, C3H/HeJ. The mice received a booster once 14 days later with the same dose of DNA. In some experiments, pregnant mice of each strain were vaccinated immediately before mating and a booster was given 2 weeks later (Chang et al., 1998).
  • Challenge Protocol: Six months after second vaccination, groups of pcDNAIE180 immunized mice were challenged intraperitoneally with a precalibrated mouse acute lethal dose of wild-type PrV-Ka TK+ (15 plaque-forming units (PFU)/g of body weight). The challenged mice were observed three times daily for clinical signs, and percent survival was assessed within 4 to 5 days postchallenge (Chang et al., 1998).
  • Efficacy: Seven months after immunization with pcDNAIE180, an overall 25% of BALB/c, C3H/HeJ, and C57BL/6 mice receiving a lethal PrV challenge were protected (Chang et al., 1998).
References
Chang et al., 1998: Chang SW, Bu J, Rompato G, Garmendia AE. A vector DNA vaccine encoding pseudorabies virus immediate early protein demonstrates partial protection in mice against lethal virus challenge. Viral immunology. 1998; 11(1); 27-36. [PubMed: 9586695].